Complementary effect of Roe's congenital heart disease treatment compared to Wade's

Published Date: 16 Feb 2023

As more states repeal or restrict abortion laws, the number of patients, the number of workers needed, and the cost of heart disease will increase. How should hospitals and policy makers prepare?

Read Full News

Latest News

sNDA for Ameluz-PDT as a Treatment for Superficial Basal Cell Carcinoma Submitted to FDA

sNDA for Ameluz-PDT as a Treatment for Superficial Basal Cell Carcinoma Submitted to FDA

INF904 Shows Strong Phase 2a Results in HS and CSU, With No Safety Signals

INF904 Shows Strong Phase 2a Results in HS and CSU, With No Safety Signals

Long-Term Course of HS Disease More Favorable Than Previous Estimates

Long-Term Course of HS Disease More Favorable Than Previous Estimates

Psoriasis Incidence Projected to Increase by 2025 Across Various Groups

Psoriasis Incidence Projected to Increase by 2025 Across Various Groups

How to Recognize and Treat Atopic Dermatitis in Patients with Skin of Color

How to Recognize and Treat Atopic Dermatitis in Patients with Skin of Color

Expert Consensus Provides Recommendations on Dermoscopy Standards for PAs

Expert Consensus Provides Recommendations on Dermoscopy Standards for PAs

Todays Updates

Nalbuphine Extended-Release Reduces Chronic Cough in IPF, with Philip Molyneaux, MBBS Philip Molyneaux, MBBS

New Phase 2 Trial to Test TREM2-Stabilizing Agent VHB937 in Alzheimer Disease Marco Meglio

A phase 2 study at CTAD 2025 explores VHB937's potential in treating early Alzheimer disease, focusing on safety and efficacy in patients.

MRI Analysis Shows Stem Cell Therapy Laromestrocel Reduced Neuroinflammation in Mild Alzheimer Disease Isabella Ciccone, MPH

In an analysis of the phase 2a CLEAR MIND study presented at CTAD 2025, laromestrocel treatment was associated with reduced hippocampal neuroinflammation in patients with mild Alzheimer disease.

Phase 3 Trial to Uncover Therapeutic Potential of 5-HT6 Antagonist Masupirdine to Treat Alzheimer Agitation Louie Pasculli

A new phase 3 clinical trial is underway to evaluate masupirdine, a selective 5-HT6 receptor antagonist, as a potential treatment for agitation in patients with Alzheimer’s disease.

Pulmonary Rehabilitation Reduces Type 2 Inflammation in High Inflammation Asthma

Pulmonary Rehabilitation Reduces Type 2 Inflammation in High Inflammation Asthma

Mental Health Apps Gain High Uptake but Struggle With Adherence, Retention

Mental Health Apps Gain High Uptake but Struggle With Adherence, Retention

6 Ophthalmology Headlines You Missed in October 2025

6 Ophthalmology Headlines You Missed in October 2025

Todays Updates

Nalbuphine Extended-Release Reduces Chronic Cough in IPF, with Philip Molyneaux, MBBS Philip Molyneaux, MBBS

New Phase 2 Trial to Test TREM2-Stabilizing Agent VHB937 in Alzheimer Disease Marco Meglio

A phase 2 study at CTAD 2025 explores VHB937's potential in treating early Alzheimer disease, focusing on safety and efficacy in patients.

MRI Analysis Shows Stem Cell Therapy Laromestrocel Reduced Neuroinflammation in Mild Alzheimer Disease Isabella Ciccone, MPH

In an analysis of the phase 2a CLEAR MIND study presented at CTAD 2025, laromestrocel treatment was associated with reduced hippocampal neuroinflammation in patients with mild Alzheimer disease.

Phase 3 Trial to Uncover Therapeutic Potential of 5-HT6 Antagonist Masupirdine to Treat Alzheimer Agitation Louie Pasculli

A new phase 3 clinical trial is underway to evaluate masupirdine, a selective 5-HT6 receptor antagonist, as a potential treatment for agitation in patients with Alzheimer’s disease.

Pulmonary Rehabilitation Reduces Type 2 Inflammation in High Inflammation Asthma

Pulmonary Rehabilitation Reduces Type 2 Inflammation in High Inflammation Asthma

Mental Health Apps Gain High Uptake but Struggle With Adherence, Retention

Mental Health Apps Gain High Uptake but Struggle With Adherence, Retention

6 Ophthalmology Headlines You Missed in October 2025

6 Ophthalmology Headlines You Missed in October 2025

Latest News

sNDA for Ameluz-PDT as a Treatment for Superficial Basal Cell Carcinoma Submitted to FDA

INF904 Shows Strong Phase 2a Results in HS and CSU, With No Safety Signals

Long-Term Course of HS Disease More Favorable Than Previous Estimates

Psoriasis Incidence Projected to Increase by 2025 Across Various Groups

How to Recognize and Treat Atopic Dermatitis in Patients with Skin of Color

Expert Consensus Provides Recommendations on Dermoscopy Standards for PAs

News All Time

Progress with Emerging TYK2 Inhibitors for Psoriasis, With Benjamin Lockshin, MD Benjamin Lockshin, MD, FAAD

Benjamin Locksin speaks in this interview about his session titled ‘Encapsulating Progress With New and Emerging TYK2 Inhibitors for Psoriasis.’

Discussing Findings on Secukinumab (Cosentyx) Efficacy Over 4 Years in HS, With Martina Porter, MD Martina Porter, MD

This interview highlights long-term, phase 3 data from the SUNSHINE and SUNRISE core and extension trials on secukinumab for hidradenitis suppurativa.

Tapinarof Shows Early, Sustained Benefits in Pediatric Atopic Dermatitis, With Druhan Howell, MD Druhan Howell, MD

At ACAAI 2025, Howell discussed sub-analytical data showing early itch and skin improvements with tapinarof cream in children with AD aged 2–17 years.

ARCADIA LTE: Long-term Nemolizumab Effective in Adolescents with Atopic Dermatitis

ARCADIA LTE: Long-term Nemolizumab Effective in Adolescents with Atopic Dermatitis

Skin of Color Savvy: A New Podcast Episode Following SOCS Media Day

Skin of Color Savvy: A New Podcast Episode Following SOCS Media Day

The HCPFive: Top News for Healthcare Providers from the Week of 11/16

The HCPFive: Top News for Healthcare Providers from the Week of 11/16

Durability of Biologics for Psoriasis Compared, Adjusted for Drug Switching Over Time

Durability of Biologics for Psoriasis Compared, Adjusted for Drug Switching Over Time

Mid Trial Update Released on Baricitinib for Frontal Fibrosing Alopecia

Mid Trial Update Released on Baricitinib for Frontal Fibrosing Alopecia

Rezpegaldesleukin Shows Strong Phase 2b Results for Atopic Dermatitis, Asthma

Rezpegaldesleukin Shows Strong Phase 2b Results for Atopic Dermatitis, Asthma

Chronic pain may increase risk of high blood pressure in adults

Chronic pain in adults may increase their risk of high blood pressure, and the location and extent of pain and if they also had depression were contributing factors, according to new research published today in Hypertension.

Potassium-enriched salt recommended for blood pressure control

The use of potassium-enriched salt has now been recommended by the National Hypertension Taskforce—Australia's peak body for blood pressure control—in a new position statement published in the Journal of Hypertension.

New 'heart percentile' calculator helps young adults grasp their long-term risk

A new Northwestern Medicine study introduces a first-of-its-kind online calculator that uses percentiles to help younger adults forecast and understand their risk of a heart event over the next 30 years. With rates of obesity, ...

Direct link between peak air pollution and cardiac risk revealed

In Lombardy, the risk of suffering cardiac arrest may increase on days recording high levels of air pollution. This emerges from a study conducted by the Politecnico di Milano and published in the journal Global Challenges.

Hypertension affects the brain much earlier than expected, study suggests

Hypertension impairs blood vessels, neurons and white matter in the brain well before the condition causes a measurable rise in blood pressure, according to a new preclinical study from Weill Cornell Medicine investigators. ...

During a heart attack, immediate stenting of other arteries isn't always necessary

A blocked coronary artery causing an acute heart attack must be opened immediately with a stent procedure. However, if other coronary arteries also appear to be narrowed, it is safe to wait and treat those later. This approach ...

Common gout drug may reduce risk of heart attack and stroke

A widely used, inexpensive gout drug could reduce heart attacks and strokes in people with cardiovascular disease, according to a new review.

Recommended News For You

Don't Call It Cancer; Clues to 'Exceptional' Responses; More Predictions for 2025

Francis Collins reveals that he was diagnosed with "aggressive" prostate cancer.

According to a study, breast cancer in Syrian refugees tends to be diagnosed at an earlier stage and with more advanced tumors.

VP Nominee Medical Records Breached; Queen Elizabeth's Cancer; Galaxy Gas Whippets

The pandemic had little impact on mental health symptoms.

The standard for high-risk prostate cancer is supported by a study using high-dose RT and long-term ADT.

Males with early-onset colorectal cancer are at risk, according to a study.

Recommended Articles For You

Hemophilia Beyond Boundaries: Unconventional Therapies in Bleeding Disorder Care 

Understanding Sepsis and Precision-Medicine-Based Immunotherapy: A Pathophysiological Perspective 

An Introduction To The CA 15-3 Tumor Marker Test For Cancer Patients 

Understanding the Role of CA 19-9 in Cancer Diagnosis and Treatment 

Whats more on Hidoc Dr.

Medical Updates
KOL Videos
Surveys
Events

Daily news to keep you up to date

Gain valuable insights with our in-depth KOL Video discussions

Participate and win cash vouchers

Get updates on the latest events happening around the world
Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Recent research suggests that vitamin supplements may increase the risk of developing cancer.

2.

One CAR T-Cell Therapy for Multiple Myeloma Tops Another in Propensity Matched Study

3.

Base-edited T-cell therapy offers additional hope for treating resistant leukemia.

4.

Gene Therapy for Rare Brain Disease Effective, but Comes With Blood Cancer Risk

5.

Three Cycles of Chemo Noninferior to Six for Rare Childhood Eye Cancer

1.

Precision Oncology: Tailoring Cancer Treatment for the Individual

2.

A Comprehensive Guide to Living with Cutaneous T Cell Lymphoma: Tips & Strategies 

3.

Breast Cancer Secrets: AI-Powered Precision Medicine

4.

New Frontiers in Diagnosing and Managing Myelodysplastic Syndromes (MASLD)

5.

Unlocking the Potential of Bicalutamide 50 mg: A Revolutionary New Treatment for Prostate Cancer

1.

International Lung Cancer Congress®

2.

Genito-Urinary Oncology Summit 2026

3.

Future NRG Oncology Meeting

4.

ISMB 2026 (Intelligent Systems for Molecular Biology)

5.

Annual International Congress on the Future of Breast Cancer East

1.

Managing ALK+ NSCLC while Ensuring Long-Term Safety of the Patients

2.

EGFR Mutation Positive Non-Small Cell Lung Cancer- Case Discussion

3.

Pazopanib Takes Center Stage in Managing Renal Cell Carcinoma - Part IV

4.

Treatment Sequencing Strategies in ALK + NSCLC Patients with CNS Diseases - Part II

5.

Post Progression Approaches After First-line Third-Generaion ALK Inhibitors

Fastest Growing Medical Platform for Doctors

Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801

Phone :
+1-415-463-3094

Email :
anishagadia@hidoc.co

Quick Links

Drug DatabaseDrug InteractionDiseases Database
KOL VideosKnowledge HubQuizzes
Medical UpdatesEventsAbout Us

© Copyright 2025 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
Home
Profile
Login
bot